Aclarion Q3 Loss Widens to $2.62M as Cash Builds to $14.2M
ACON is trading near its 52-week low of $1.544 (1.0% above the low) on light trading volume (0.3× avg).
Summary
Aclarion's Q3 2026 loss widened to $2.62 million on an 82% jump in G&A, while revenue rose 78.1% to $33,733 and cash stood at $14.2 million — enough, management says, for at least twelve months.
Key Events · Earnings and Guidance · ACON
-
Q3 Loss Widens on Cost Surge
Net loss was $2,622,035 for the three months ended September 30, 2026 versus $1,706,294 a year earlier; nine-month loss reached $8,223,161 from $5,344,487.
-
Revenue Up but Still Tiny
Net revenue rose 78.1% to $33,733 in Q3 and 39.9% to $80,081 for nine months, driven by NOCISCAN reports sold into the UK market after local coverage decisions.
-
G&A Jumped 82%
General and administrative expense was $1,639,456 in Q3 versus $900,904, with salaries and benefits up 146.6% to $1,039,447 and stock-based compensation of $299,544 versus $16,746.
-
Cash Covers Twelve Months
Cash, cash equivalents and restricted cash totaled $14,212,566 at September 30, 2026; management states this funds operating expenses and capital expenditures for at least twelve months from issuance.
Analysis · ACON · Industrial Applications And Services
The headline for Aclarion is the widening loss: $2.62 million in the third quarter versus $1.71 million a year earlier, and $8.22 million for nine months against $5.34 million. An 82% jump in general and administrative costs — tied to salaries, stock compensation and bonus accruals — drove the deterioration. Revenue, however, is finally moving: $33,733 in the quarter, up 78.1%, and $80,081 for nine months, up 39.9%, as NOCISCAN reports sold into the UK market following local coverage decisions. For a company this size, the balance sheet is the real story — $14.2 million of cash and restricted cash at September 30, 2026, after a $10.4 million January registered direct offering, which management says funds at least twelve months of operations. That runway claim is what keeps the equity story alive. The offset: the January raise was priced at $5.18 per share versus a stock now trading near $1.56, so the dilution was taken at a much higher valuation than the market currently assigns.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ACON was trading at $1.56 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $4.5M. The 52-week trading range was $1.54 to $9.36. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.